Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Recommedations for the use of abatacept in patients with rheumatoid arthritis].

× No keyword cloud information.

11 in total

1. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

Authors: M Weinblatt; B Combe; A Covucci; R Aranda; J C Becker; E Keystone
Journal: Arthritis Rheum Date: 2006-09

2. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].

Authors: B Manger; H Michels; H G Nüsslein; M Schneider; J Sieper
Journal: Z Rheumatol Date: 2007-02 Impact factor: 1.372

Review 3. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal: Ann Rheum Dis Date: 2007-11 Impact factor: 19.103

4. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.

Authors: Michael Weinblatt; Michael Schiff; Allan Goldman; Joel Kremer; Michael Luggen; Tracy Li; Dalei Chen; Jean-Claude Becker
Journal: Ann Rheum Dis Date: 2006-08-25 Impact factor: 19.103

5. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

Authors: Joel M Kremer; Harry K Genant; Larry W Moreland; Anthony S Russell; Paul Emery; Carlos Abud-Mendoza; Jacek Szechinski; Tracy Li; Zhiyu Ge; Jean-Claude Becker; Rene Westhovens
Journal: Ann Intern Med Date: 2006-06-20 Impact factor: 25.391

6. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

Authors: Joel M Kremer; Maxime Dougados; Paul Emery; Patrick Durez; Jean Sibilia; William Shergy; Serge Steinfeld; Elizabeth Tindall; Jean-Claude Becker; Tracy Li; Isaac F Nuamah; Richard Aranda; Larry W Moreland
Journal: Arthritis Rheum Date: 2005-08

7. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.

Authors: Larry W Moreland; Rieke Alten; Filip Van den Bosch; Thierry Appelboom; Marc Leon; Paul Emery; Stanley Cohen; Michael Luggen; William Shergy; Isaac Nuamah; Jean-Claude Becker
Journal: Arthritis Rheum Date: 2002-06

8. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.

Authors: Helen G Haggerty; Mark A Abbott; Timothy P Reilly; Deborah A DeVona; Carol R Gleason; Lee Tay; Robert Dodge; Richard Aranda
Journal: J Rheumatol Date: 2007-11-15 Impact factor: 4.666

9. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Authors: M Schiff; M Keiserman; C Codding; S Songcharoen; A Berman; S Nayiager; C Saldate; T Li; R Aranda; J-C Becker; C Lin; P L N Cornet; M Dougados
Journal: Ann Rheum Dis Date: 2007-11-29 Impact factor: 19.103

Review 10. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Authors: C Salliot; M Dougados; L Gossec
Journal: Ann Rheum Dis Date: 2008-01-18 Impact factor: 19.103

1 in total

1. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].

Authors: J Wollenhaupt; K Krüger
Journal: Z Rheumatol Date: 2010-09 Impact factor: 1.372

1 in total